{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:07:38Z","timestamp":1777421258585,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review the pharmacology, efficacy, and safety of ubrogepant as an abortive migraine treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>A literature search of MEDLINE and PubMed was performed (January 2006 through May 2021) using the following search terms: ubrogepant, calcitonin gene related peptide, and abortive migraine therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>Relevant studies evaluating ubrogepant\u2019s pharmacology, efficacy, and safety in humans for the treatment of migraine were considered<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis<\/jats:title>\n                    <jats:p>Ubrogepant is a calcitonin gene-related peptide receptor antagonist approved by the Food and Drug Administration for the acute treatment of migraine via data from ACHIEVE I and II. From ACHIEVE I, ubrogepant demonstrated superiority to placebo in freedom from migraine pain at 2 hours postdose (50-mg dose: odds ratio [OR] = 1.83, 95% CI = 1.25-2.66; 100-mg dose: OR = 2.04, 95% CI = 1.41-2.95) and freedom from most bothersome symptom (MBS; 50-mg dose: OR = 1.70, 95% CI = 1.27-2.28; 100-mg dose: OR = 1.63, 95% CI = 1.22-2.17). ACHIEVE II trial demonstrated efficacy of ubrogepant 50 mg compared with placebo (2-hour pain freedom: OR = 1.62, 95% CI = 1.14-2.29; 2-hour MBS freedom: OR = 1.65, 95% CI = 1.25-2.20).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice<\/jats:title>\n                    <jats:p>Ubrogepant is a viable option for patients who are unable to tolerate nonsteroidal anti-inflammatory drug or triptan therapy because of ineffective relief or contraindications that limit use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ubrogepant is a well-tolerated effective abortive migraine treatment that bridges a gap in therapy for many patients who previously could not tolerate other first-line treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280211023810","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T05:18:42Z","timestamp":1623302322000},"page":"346-351","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Ubrogepant: An Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for Abortive Migraine Treatment"],"prefix":"10.1177","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1673-2228","authenticated-orcid":false,"given":"Madell","family":"Nedd","sequence":"first","affiliation":[{"name":"Winter Haven Hospital, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Garland","sequence":"additional","affiliation":[{"name":"BayCare Health System, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Falk","sequence":"additional","affiliation":[{"name":"BayCare Health System, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Wilk","sequence":"additional","affiliation":[{"name":"BayCare Health System, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"bibr1-10600280211023810","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01945.x"},{"key":"bibr2-10600280211023810","doi-asserted-by":"publisher","DOI":"10.1111\/head.13421"},{"key":"bibr3-10600280211023810","doi-asserted-by":"publisher","DOI":"10.1111\/head.12550"},{"key":"bibr4-10600280211023810","doi-asserted-by":"publisher","DOI":"10.1111\/head.12601"},{"key":"bibr5-10600280211023810","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.000000000000019"},{"key":"bibr6-10600280211023810","unstructured":"UBRELVY. Package insert. Allergan USA, Inc; 2020."},{"key":"bibr7-10600280211023810","unstructured":"Micromedex. Ubrogepant. Accessed May 29, 2021. https:\/\/www.micromedexsolutions.com"},{"key":"bibr8-10600280211023810","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416653233"},{"key":"bibr9-10600280211023810","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"bibr10-10600280211023810","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"bibr11-10600280211023810","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"bibr12-10600280211023810","volume-title":"Paper Presented at: American Headache Society","author":"Blumenfeld AM"},{"key":"bibr13-10600280211023810","doi-asserted-by":"publisher","DOI":"10.1111\/head.13766"},{"key":"bibr14-10600280211023810","doi-asserted-by":"publisher","DOI":"10.1111\/head.13682"},{"key":"bibr15-10600280211023810","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1696"},{"key":"bibr16-10600280211023810","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0979"},{"key":"bibr17-10600280211023810","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280211023810","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280211023810","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280211023810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:18Z","timestamp":1777374978000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280211023810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1177\/10600280211023810"],"URL":"https:\/\/doi.org\/10.1177\/10600280211023810","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]}}}